.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Obtain formulation and manufacturing information
  • Drug patents and clinical trials in dozens of countries

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Daiichi Sankyo
Moodys
QuintilesIMS
Chubb
Chinese Patent Office
Healthtrust
Fuji
US Department of Justice
Dow

Generated: June 24, 2017

DrugPatentWatch Database Preview

ONZETRA XSAIL Drug Profile

« Back to Dashboard

What is the patent landscape for Onzetra Xsail, and when can generic versions of Onzetra Xsail launch?

Onzetra Xsail is a drug marketed by Avanir Pharms and is included in one NDA. There are thirteen patents protecting this drug.

This drug has two hundred and twenty-three patent family members in twenty-eight countries.

The generic ingredient in ONZETRA XSAIL is sumatriptan succinate. There are twenty-three drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.

Summary for Tradename: ONZETRA XSAIL

Patents:13
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list103
Patent Applications: see list4,924
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ONZETRA XSAIL at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Avanir Pharms
ONZETRA XSAIL
sumatriptan succinate
POWDER;INHALATION206099-001Jan 27, 2016RXYesYes9,119,932► SubscribeY ► Subscribe
Avanir Pharms
ONZETRA XSAIL
sumatriptan succinate
POWDER;INHALATION206099-001Jan 27, 2016RXYesYes9,108,015► SubscribeY ► Subscribe
Avanir Pharms
ONZETRA XSAIL
sumatriptan succinate
POWDER;INHALATION206099-001Jan 27, 2016RXYesYes8,550,073► SubscribeY ► Subscribe
Avanir Pharms
ONZETRA XSAIL
sumatriptan succinate
POWDER;INHALATION206099-001Jan 27, 2016RXYesYes7,975,690► SubscribeY ► Subscribe
Avanir Pharms
ONZETRA XSAIL
sumatriptan succinate
POWDER;INHALATION206099-001Jan 27, 2016RXYesYes8,899,229► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ONZETRA XSAIL

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,841,337Breath-actuated nasal delivery device► Subscribe
9,144,652Powder delivery devices► Subscribe
7,481,218Nasal devices► Subscribe
8,522,778Nasal devices► Subscribe
8,555,878Nasal delivery device► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ONZETRA XSAIL

Country Document Number Estimated Expiration
Turkey200102563► Subscribe
Australia2002255224► Subscribe
Australia2007202918► Subscribe
Japan2008513078► Subscribe
Poland203959► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Merck
Dow
Cantor Fitzgerald
Cerilliant
Teva
McKinsey
Mallinckrodt
Baxter
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot